Recent medical studies showed that the COVID-19 vaccines manufactured in China by Sinopharm and Sinovac Biotech lack the ability to cause production of sufficient neutralizing antibodies to combat the rapid spread of Omicron variants of the virus. The neutralizing antibodies are substances that bind to pathogens and prevent them from infecting others. One of the most important indicators for vaccine effectiveness is its level of production.
Currently, the two most commonly used vaccines are Sinopharm’s BBIBP–CorV vaccine (Sinovac Biotech’s CoronaVac vaccine) and Sinopharm’s BBIBP–CorV vaccine. Both vaccines, despite their flaws, are used in China and exported to many other countries.
The June 20 issue of The Lancet Infectious Diseases journal included a report on the efficacy of Sinopharm’s BBIBO-CorV vaccine. Led by 10 Chinese medical experts, the report tracked the health of 25 subjects and the levels of antibodies they produced, after receiving the vaccine. The vaccine should cause sufficient antibody production to neutralize Omicron BA.2 subtypes. 12.1 and BA.4/BA.5.
After administering two doses Sinopharm’s vaccine, researchers discovered that the neutralizing antibodies in recipient blood were either not detectable or undetectable. After a booster shot, less than half (ranging from 24 to 48 percent) of the 25 subjects had antibodies to the Omicron subtype variants.
On January 20, Nature Medicine journal published a report comparing the efficacy of Sinovac Biotech’s CoronaVac vaccine and Pfizer Biotech’s mRNA Comirnaty vaccine. The report was co-authored by Yale University researchers and Dominican Republic scientists. It found that CoronaVac alone didn’t prevent the spread of Omicron variants.
The study analyzed the sera of 101 people from the Dominican Republic and showed that those who received two doses of the CoronaVac vaccine did not develop neutralizing antibodies against Omicron. However, the antibodies to Omicron were higher in those who had received booster shots and vaccines from Pfizer.
Researchers compared study samples to serum and blood samples at Yale University. They found that those who had received CoronaVac plus an additional booster had comparable levels of antibodies as those who were given two doses without the booster.
Last Dec , Medical researchers at Shanghai’s Jiao Tong University, and a Shanghai-based laboratory that specializes in respiratory infections diseases examined Sinopharm’s BBIBP CorV booster against Omicron. They also compared it to an older Wuhan coronavirus strain. The booster’s neutralizing antibodies activity against Omicron dropped by 20.1 times compared to its activity against the older Wuhan strain.
The study analyzed samples from 292 health care workers who received a third CoronaVac booster 8 to 9 months after receiving their second dose.
China’s Vaccination Rate Exceeds the Rate Required to Achieve Herd Immunity
Herd immunity is when an overwhelming number of people are immune to the same disease. This helps to prevent spread to other more vulnerable populations. It is therefore important that vaccines administered have high efficacy.
As of June 20, the Chinese Central Government’s official web portal claims that 3.4 billion doses of vaccines have been administered to a population of 1.4 billion. This vaccination rate is unmatched in any other country, which suggests that China might have achieved herd immunity.
One month prior to this claim, the Xinhua News Agency said that 91.2 percent of China’s population has received the initial COVID-19 vaccine while 88. 74 percent have received the full regimen of boosters. As for people over the age of 60, 86. 23 percent have received one dose of the vaccine and 81. 67 percent have received the full regimen of doses.
According to the World Health Organization (WHO), only 57 countries have achieved a 70 percent vaccination rate. Despite China claiming widespread vaccination, the Chinese Communist Party continues to insist on its strict zero-Covid policy.
Julia Ye is an Australian-based reporter who joined The Epoch Times in 2021. She mainly covers China-related issues and has been a reporter since 2003.